XML 126 R18.htm IDEA: XBRL DOCUMENT v3.20.4
Other disclosures (Tables)
 12 Months Ended
Dec. 31, 2020
Additional information [abstract]  
Expensed in the Income statement
Share-based payment expensed in the income statement
DKK million202020192018
Restricted stock units to employees18948204
Long-term share-based incentive programme (Management Board)1
1628648
Long-term share-based incentive programme (management group below Management Board)436195145
Shares allocated to individual employees363417
Share-based payment expensed in the income statement823363414
1. In 2017 Novo Nordisk introduced, for the first time, a share-based compensation programme with terms which amortises the grant date valuation over four years. The 2020 expense includes amortisation of the 2017, 2018, 2019 and 2020 programmes.
General Terms and Conditions of Launched Programmes
General terms and conditions of launched programmes
Restricted stock units to employeesShares for Management BoardShares for management group below Management BoardShares allocated to individual employees
202020192018202020192018202020192018202020192018
Number of shares awarded in the year— 2,148,580 — 370,038 508,398 411,090 1,011,6921,300,333 1,114,455 43,790 154,122 159,437 
Value per share at launch (DKK)— 307 — 411 298 280 411 298 280 391 311 278 
Total market value at launch (DKK million)— 660 — 152 152 115 416 387 312 17 48 44 
Amortisation period of the programme
2019 to 20232020 to 20232019 to 20222018 to 20212020 to 20232019 to 20222018 to 20212020 to 20232019 to 20222018 to 2021
Allocated to recipientsFeb 2023Feb 2024Feb 2023Feb 2022Feb 2024Feb 2023Feb 2022202320222021
Vesting period— 3.5 years—3 years3 years3 years3 years3 years3 years3 years3 years3 years
Outstanding Restricted Stock
Outstanding restricted stock unitsTotalRestricted stock units to employeesShares for Management BoardShares for management group below Management BoardShares allocated to individual employees
202020192018202020192018202020192018202020192018202020192018
Outstanding at the beginning of the year6,879,198 5,584,019 4,933,882 2,148,580 1,521,031 1,556,211 1,326,080 1,228,714 1,115,494 3,173,185 2,665,226 2,226,683 231,353 169,048 35,494 
Released allocated shares(361,844)(2,553,658)(825,537)(29,250)(1,431,192)(35,180)(95,082)(378,421)(284,173)(171,162)(662,172)(480,301)(66,350)(81,873)(25,883)
Cancelled allocated shares(129,713)(262,596)(209,308)— (89,839)— (12,700)(32,611)(13,697)(95,038)(130,202)(195,611)(21,975)(9,944)— 
Allocated in the year1,425,520 4,111,433 1,684,982 — 2,148,580 — 370,038 508,398 411,090 1,011,692 1,300,333 1,114,455 43,790 154,122 159,437 
Performance adjustment1
863,557 — — — — — 239,567 — — 623,990 — — — — — 
Outstanding at the end of the year8,676,718 6,879,198 5,584,019 2,119,330 2,148,580 1,521,031 1,827,903 1,326,080 1,228,714 4,542,667 3,173,185 2,665,226 186,818 231,353 169,048 
1. Number of shares for Management Board and management group below Management board has been adjusted as the sales growth target set by the Board is expected to be exceeded for the 2018, 2019 and 2020 programmes.
Contractual Obligations and Recognised Non-Current Debt
Total contractual obligations and recognised non-current debt can be specified as follows (payments due by period):
20202019
DKK millionWithin
1 year		 1-3
years		3-5
years		More
than
5 years		TotalWithin
1 year		1-3
years		3-5
years		More
than
5 years		Total
Retirement benefit obligations2346441,2861,3991326251,2701,334
Leases (note 4.4)
8551,2476941,2414,0378471,4247341,1404,145
Total obligations recognised in the balance sheet8781,2937382,5275,4368601,4507592,4105,479
Leases1
152198134280764128229199376932
Research and development obligations2,7333,4609051377,2352,6003,2581,493297,380
Research and development – potential milestone payments2
2059185072,4534,0833001,0231,0092,4034,735
Commercial product launch – potential milestone payments2
——2125,8936,105———3,4683,468
Purchase obligations relating to invest-
ments in property, plant and equipment		339———339172———172
Other purchase obligations7,5283,01477374812,0635,6952,9891,17562110,480
Total obligations not recognised in the balance sheet10,9577,5902,5319,51130,5898,8957,4993,8766,89727,167
Total contractual obligations11,8358,8833,26912,03836,0259,7558,9494,6359,30732,646
1. Predominantly relates to estimated variable property taxes, leases committed not yet commenced and low value assets.
2. Potential milestone payments are associated with uncertainty as they are linked to successful achievements in research activities.
Material Transactions with Related Parties
Material transactions with related parties
DKK million202020192018
Novo Holdings A/S
Purchase of Novo Nordisk B shares5,9634,8944,207
Sale of NNIT B shares——(368)
Dividend payment to Novo Holdings A/S5,7675,5805,496
NNIT Group
Services provided by NNIT7759411,052
Dividend payment from NNIT(18)(20)(19)
Novozymes Group
Services provided by Novo Nordisk(113)(132)(115)
Services provided by Novozymes72103121
CS Solar Fund XIV
Purchase of shares by Novo Nordisk—97—
Liability for capital commitment1
—389—
Distribution by CS Solar Fund XIV—(385)—
1. The liability disclosed for 2019 related to capital commitment was paid in 2020 (DKK 392 million).
Schedule of Auditors' Remuneration
DKK million202020192018
Statutory audit262625
Audit-related services343
Tax advisory services91111
Other services443
Total fee to statutory auditors424542
Schedule of Companies Included in Novo Nordisk Group
Activity: • Sales and marketing• Production
• Research and development• Services/investments
Company and countryPercentage of shares ownedActivity
Parent company
Novo Nordisk A/S, Denmark••••
Subsidiaries by geographical area
North America Operations
Novo Nordisk Canada Inc., Canada100•
Novo Nordisk Inc., United States100•
Novo Nordisk North America Operations A/S, Denmark100•
Novo Nordisk Pharmaceutical Industries LP, United States100•
Novo Nordisk Pharma, Inc., United States100•
Novo Nordisk Research Center Indianapolis, Inc., United States100•
Novo Nordisk Research Center Seattle, Inc., United States100•
Novo Nordisk US Bio Production, Inc., United States100•
Novo Nordisk US Commercial Holdings, Inc., United States100•
Novo Nordisk US Holdings Inc., United States100•
Corvidia Therapeutics, Inc., United States100•
Emisphere Technologies, Inc., United States100•
International Operations
Novo Nordisk Pharmaceuticals A/S, Denmark100•
Novo Nordisk Pharma Operations A/S, Denmark100••
Novo Nordisk Region AAMEO and LATAM A/S, Denmark100•
Novo Nordisk Region Europe A/S, Denmark100•
Novo Nordisk Region Japan & Korea A/S, Denmark100•
EMEA
Aldaph SpA, Algeria100••
Novo Nordisk Pharma GmbH, Austria100•
S.A. Novo Nordisk Pharma N.V., Belgium100•
Novo Nordisk Pharma d.o.o., Bosnia and Herzegovina100•
Novo Nordisk Pharma EAD, Bulgaria100•
Novo Nordisk Hrvatska d.o.o., Croatia100•
Novo Nordisk s.r.o., Czech Republic100•
Novo Nordisk Denmark A/S, Denmark100•
Novo Nordisk Pharmatech A/S, Denmark100••
Novo Nordisk Egypt LLC, Egypt100•
Novo Nordisk Farma OY, Finland100•
Novo Nordisk, France100•
Novo Nordisk Production SAS, France100•
Novo Nordisk Pharma GmbH, Germany100•
Novo Nordisk Hellas Epe., Greece100•
Novo Nordisk Hungária Kft., Hungary100•
Novo Nordisk Biopharm Limited, Ireland100••
Novo Nordisk Limited, Ireland100•
Company and countryPercentage of shares ownedActivity
Novo Nordisk Ltd, Israel100•
Novo Nordisk S.P.A., Italy100•
Novo Nordisk Kazakhstan LLP, Kazakhstan100•
Novo Nordisk Kenya Ltd., Kenya100•
Novo Nordisk Pharma SARL, Lebanon100•
UAB Novo Nordisk Pharma, Lithuania100•
Novo Nordisk Farma dooel, North Macedonia100•
Novo Nordisk Pharma SAS, Morocco100•
Novo Nordisk B.V., Netherlands100•
Novo Nordisk Pharma Limited, Nigeria100•
Novo Nordisk Norway AS, Norway100•
Novo Nordisk Pharmaceutical Services Sp. z o.o., Poland100•
Novo Nordisk Pharma Sp.z.o.o., Poland100•
Novo Nordisk Comércio Produtos Farmacêuticos Lda., Portugal100•
Novo Nordisk Farma S.R.L., Romania100•
Novo Nordisk Limited Liability Company, Russia100•
Novo Nordisk Production Support LLC, Russia100•
Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Serbia100•
Novo Nordisk Slovakia s.r.o., Slovakia100•
Novo Nordisk, d.o.o., Slovenia100•
Novo Nordisk (Pty) Limited, South Africa100•
Novo Nordisk Pharma S.A., Spain100•
Novo Nordisk Scandinavia AB, Sweden100•
Novo Nordisk Health Care AG, Switzerland100••
Novo Nordisk Pharma AG, Switzerland100•
Novo Nordisk Tunisie SARL, Tunisia100•
Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Turkey100•
Novo Nordisk Ukraine, LLC, Ukraine100•
Novo Nordisk Pharma Gulf FZ-LLC, United Arab Emirates100•
Novo Nordisk Holding Limited, United Kingdom100•
Novo Nordisk Limited, United Kingdom100•
Ziylo Limited, United Kingdom100•
Region China
Novo Nordisk (China) Pharmaceuticals Co., Ltd., China100••
Novo Nordisk Region China A/S, Denmark100•
Beijing Novo Nordisk Pharmaceuticals Science & Technology Co., Ltd., China100•
Novo Nordisk Hong Kong Limited, Hong Kong100•
Novo Nordisk Pharma (Taiwan) Ltd., Taiwan100•
Company and countryPercentage of shares ownedActivity
Rest of World
Novo Nordisk Pharma Argentina S.A., Argentina100 •
Novo Nordisk Pharmaceuticals Pty. Ltd., Australia100 •
Novo Nordisk Pharma (Private) Limited, Bangladesh100 •
Novo Nordisk Produção Farmacêutica do Brasil Ltda., Brazil100 •
Novo Nordisk Farmacêutica do Brasil Ltda., Brazil100 •
Novo Nordisk Farmacéutica Limitada, Chile100 •
Novo Nordisk Colombia SAS, Colombia100 •
Novo Nordisk India Private Limited, India100 •
Novo Nordisk Service Centre (India) Pvt. Ltd., India100 •
PT. Novo Nordisk Indonesia, Indonesia100 •
Novo Nordisk Pars, Iran100 ••
Novo Nordisk Pharma Ltd., Japan100 ••
Novo Nordisk Pharma (Malaysia) Sdn Bhd, Malaysia100 •
Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Malaysia100 •
Novo Nordisk Mexico S.A. de C.V., Mexico100 •
Novo Nordisk Pharmaceuticals Ltd., New Zealand100 •
Novo Nordisk Pharma (Private) Limited, Pakistan100 •
Novo Nordisk Panama S.A., Panama100 •
Novo Nordisk Peru S.A.C., Peru100 •
Novo Nordisk Pharmaceuticals (Philippines) Inc., Philippines100 •
Novo Nordisk Pharma (Singapore) Pte Ltd., Singapore100 •
Novo Investment Pte Limited, Singapore100 •
Novo Nordisk Pharma Korea Ltd., South Korea100 •
Novo Nordisk Lanka (PVT) Ltd, Sri Lanka100 •
Novo Nordisk Pharma (Thailand) Ltd., Thailand93 •
Novo Nordisk Venezuela Casa de Representación C.A., Venezuela100 •
Other subsidiaries and associated companies
NNE A/S, Denmark100 •
NNIT A/S, Denmark18 •
Churchill Stateside Solar Fund XIV, LLC, United States99 •